#58
Measured Relevance
This is a randomized trial of CBD isolate and sleep-related symptoms, but the sample was small, the outcome was self-reported, and the 300 mg dose did not clearly beat placebo.
CBD for sleep disturbances remains an evidence-light topic. This paper is useful because it compares a commercial-like dose with a much higher dose and placebo, but its signal is still too soft to treat as proof of clinical efficacy.
CBD Isolate
Sleep Disturbances
Trait Worry
Randomized Trial
| Audience | Patients, clinicians, cannabis-curious readers, sleep-focused readers |
| Primary Topic | CBD for sleep disturbances |
| Source | Read the full article |
Table of Contents
- CBD for Sleep Disturbances: What This Randomized Trial Really Shows
- Frequently Asked Questions About CBD for Sleep Disturbances
- Did this study prove that CBD improves sleep?
- What dose looked most promising here?
- Did 50 mg CBD help sleep in this trial?
- Were participants people with insomnia?
- Did the study measure objective sleep?
- Did CBD cause sedation in this study?
- Did CBD impair cognition here?
- How long did participants take CBD?
- Why does the placebo comparison matter so much?
- What would a stronger next study look like?
- Frequently Asked Questions About CBD for Sleep Disturbances
CBD for Sleep Disturbances: What This Randomized Trial Really Shows
CBD for sleep disturbances is widely discussed, widely marketed, and still not well settled scientifically. In this small double-blind randomized placebo-controlled trial of high-trait worriers, 300 mg CBD looked better than 50 mg CBD over 2 weeks, but it did not show a statistically significant advantage over placebo, which makes the paper informative, yet far from definitive.
This paper is a secondary analysis of a randomized, double-blind, placebo-controlled trial, which gives it more value than anecdotes or open-label case series. It asked a practical question many readers actually care about: does a common commercial-style CBD dose work differently from a much higher dose, and does either beat placebo?
The main teaching point is narrow but useful. Over 2 weeks, 300 mg CBD improved self-reported sleep disturbance scores more than 50 mg CBD, but not more than placebo, so the study supports dose sensitivity more than it supports efficacy.
It also teaches restraint. The population was not a classic insomnia cohort, the sleep outcomes were subjective, the sample was small, and the trial was not preregistered, so this is better viewed as a signal-generating paper than as a practice-changing one.
For the public: Many CBD products for sleep are sold at relatively low doses, often with an implied promise that they will predictably improve rest. This study suggests that if CBD has a meaningful signal here, it may not show up reliably at lower doses, and even at 300 mg the improvement did not clearly outperform placebo.
For clinicians: Patients frequently ask whether CBD is a gentler sleep aid that avoids next-day grogginess or cognitive dulling. This trial gives some reassurance that sedation and cognitive impairment were not increased here, but it does not justify a confident therapeutic recommendation for CBD for sleep disturbances in routine practice.
For researchers and careful readers: The paper highlights how easily a CBD-sleep narrative can be overstated. A result that is stronger than one active dose but not stronger than placebo is interesting, yet it is not the same as proving a treatment effect, especially when the study relies on self-report in a specialized sample.
| Study Type | Secondary analysis of a double-blind, randomized, placebo-controlled trial |
| Population | Adults aged 18 to 55 with elevated trait worry, mean age 29.27 years, recruited from the community; mostly White and relatively well educated |
| Exposure or Intervention | CBD isolate softgels given twice daily for 2 weeks, totaling either 300 mg/day or 50 mg/day |
| Comparator | Placebo softgels matched to preserve blinding; active dose comparison between 300 mg and 50 mg CBD |
| Primary Outcomes | Self-reported sleep disturbances and sleep quality on the PROMIS Sleep Disturbance Short Form; secondary outcomes were self-reported sedation and cognitive impairment |
| Sample Size or Scope | 63 participants in the final dataset, 21 per arm, after replacements for dropout or noncompliance |
| Journal | Experimental and Clinical Psychopharmacology |
| Year | 2026, published online first February 12, 2026 |
| DOI | 10.1037/pha0000832 |
| Funding or Conflicts | Study funding from Canopy Growth Corporation; one author reported personal fees from Canopy Growth and Charlotteโs Web; another disclosed that a partner was employed by Canopy Growth during data collection; authors stated a conflict-management plan was used |
This trial does not establish CBD as an evidence-backed sleep treatment. At most, it suggests that a higher CBD isolate dose may behave differently from a lower dose, while still leaving open the possibility that much of the observed benefit was placebo-related.
The investigators enrolled adults with elevated trait worry, not a broad community sleep sample and not a formally defined insomnia population. Participants were randomized to 300 mg/day CBD isolate, 50 mg/day CBD isolate, or placebo for 2 weeks, with twice-daily dosing and compliance monitoring through video verification. The main question was whether sleep disturbance scores changed differently across groups, and whether CBD caused sedation or cognitive problems along the way.
All groups improved somewhat over time. The 300 mg group showed a greater reduction in PROMIS sleep disturbance scores than the 50 mg group, but the 300 mg group did not show a statistically significant advantage over placebo in post hoc comparison. The 50 mg dose did not differ meaningfully from placebo. Sedation and cognitive impairment did not worsen in a detectable way across CBD groups, and reported side effects were not significantly different between conditions. In the middle of the clinical conversation about CBD for sleep disturbances, that pattern matters: it suggests dosage may matter, but it still does not prove that CBD itself, independent of expectancy and study context, meaningfully improved sleep.
By design, this sits above surveys, testimonials, and uncontrolled case reports because it is randomized, blinded, and placebo-controlled. Still, it is not especially strong confirmatory evidence because the sample was small, the study was a secondary analysis rather than a trial designed primarily around sleep endpoints, the outcomes were subjective, and the key placebo comparison was not statistically convincing. Clinically, this is early human evidence that is worth knowing about, not evidence that should settle the question.
The first caution is conceptual. This was not a direct trial of people selected because they had clinically significant insomnia, and sleep was assessed through self-report rather than actigraphy or polysomnography. That matters because worried people can experience meaningful shifts in perceived sleep that do not necessarily reflect objective sleep architecture or durable treatment benefit.
The second caution is statistical and interpretive. The headline-friendly comparison is that 300 mg beat 50 mg, but the clinically harder comparison is 300 mg versus placebo, and that did not hold up as statistically significant in post hoc pairwise trend comparison. Add to that a small sample, short duration, no preregistration, and industry-linked funding disclosures, and the paper becomes something to weigh carefully rather than something to quote triumphantly.
It does not show that CBD is an established treatment for insomnia. It does not show that common over-the-counter sleep CBD doses work. It does not show objective sleep improvement, long-term benefit, superiority to standard insomnia care, or generalizability to older adults, medically complex patients, or typical clinical sleep populations.
This is a worthwhile paper because it narrows the question and avoids some of the sloppiness that often clouds cannabis research. Still, the cleanest conclusion is modest: a 300 mg CBD isolate dose may show more movement than 50 mg in worried adults over 2 weeks, but this trial does not establish a clear placebo-beating benefit. Readers should come away more informed about the uncertainty, not less.
๐ฌ Join the Conversation
Want help thinking through whether sleep symptoms, anxiety, dosing, or product type may be more relevant in your case? Ask Dr. Caplan โ
Interested in the broader discussion around evidence and cannabis care? Join the forum discussion โ
Have thoughts on this? Share it:
Frequently Asked Questions About CBD for Sleep Disturbances
Did this study prove that CBD improves sleep?
No. The higher dose performed better than the lower dose, but it did not show a statistically significant advantage over placebo.
What dose looked most promising here?
The 300 mg/day CBD isolate arm showed more improvement than the 50 mg/day arm over 2 weeks.
Did 50 mg CBD help sleep in this trial?
Not convincingly. The 50 mg arm did not differ meaningfully from placebo.
Were participants people with insomnia?
No. They were adults with elevated trait worry, which may overlap with sleep problems but is not the same as a defined insomnia population.
Did the study measure objective sleep?
No. The main sleep outcome was self-reported, not polysomnography or actigraphy.
Did CBD cause sedation in this study?
No clear sedation signal emerged. Sedation scores did not worsen significantly across the CBD groups.
Did CBD impair cognition here?
No clear cognitive impairment signal was detected on the studyโs self-reported cognitive scale.
How long did participants take CBD?
For 2 weeks. That is helpful for a short-term signal but too brief to answer longer-term efficacy questions.
Why does the placebo comparison matter so much?
Because sleep symptoms are highly vulnerable to expectancy effects, routine fluctuations, and perceived improvement. A therapy that does not clearly beat placebo remains uncertain.
What would a stronger next study look like?
A preregistered trial in people with clinically meaningful sleep disturbances, using larger samples, longer follow-up, and objective sleep measures alongside patient-reported outcomes.